Wiener klinische Wochenschrift

, Volume 119, Issue 19–20, pp 564–569

Diagnosis and differential diagnosis of hypergastrinemia

Article

Summary

The most frequent conditions of hypergastrinemia in man are the Zollinger-Ellison syndrome with autonomous gastrin hypersecretion by the tumour cell and reactive hypergastrinemia in type A autoimmune chronic atrophic gastritis with achlorhydria causing unrestrained gastrin release from the gastrin-producing antral G-cells. Both entities differ with respect to the pH in the gastric fluid, which is < 2 in patients with Zollinger-Ellison syndrome and neutral in type A gastritis. Other conditions with moderate hypergastrinemia as treatment with proton pump inhibitors, gastric outlet obstruction, previous vagotomy, chronic renal failure or short bowel syndrome are of minor clinical importance.

Keywords

Hypergastrinemia Zollinger-Ellison syndrome Chronic atrophic gastritis Type A gastritis 

Diagnose und Differentialdiagnose der Hypergastrinämie

Zusammenfassung

Die häufigste Ursache für einen erhöhten Gastrinspiegel beim Menschen sind das Zollinger-Ellison Syndrom mit autonomer Gastrinüberproduktion durch einen Tumor und die reaktive Hypergastrinämie im Rahen einer chronisch atrophen Autoimmun-(Typ A) Gastritis. Die Achlorhydrie bewirkt eine vermehrte Gastrinausschüttung durch die antralen G-Zellen. Die Entitäten unterscheiden sich durch den pH Wert der Magensäure. Dieser ist < 2 bei Vorliegen eines Zollinger-Ellison Syndroms und neutral bei der Typ A Gastritis. Die Behandlung mit Protonen Pumpen Inhibitoren, eine Magenausgangsstenose, eine Vagotomie, chronische Niereninsuffizienz oder ein Kurzdarmsyndrom können mit einer milden Hypergastrinämie ohne klinische Relevanz einhergehen.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Larsson LI (1980) Gastrointestinal cells producing endocrine, neurocrine and paracrine messengers. Clin Gastroenterol 9: 485–516PubMedGoogle Scholar
  2. Saffouri B, Weir G, Bitar K, Makhlouf G (1979) Stimulation of gastrin secretion from perfused rat stomach by somatostatin antiserum. Life Sci 25: 1749–1753PubMedCrossRefGoogle Scholar
  3. Arnold R, Koop H (1991) The interrelationship between somatostatin cells and gastrin cells. In: Hakanson R, Sundler F (eds) The stomach as an endocrine organ, Elsevier Science Publishers (Biomedical Division), pp 111–119Google Scholar
  4. Arnold R, Hülst MV, Neuhof CH, Schwarting H, Becker HD, Creutzfeldt W (1982) Antral gastrin-producing G-cells and somatostatin-producing D-cells in different states of acid secretion. Gut 23: 285–291PubMedCrossRefGoogle Scholar
  5. Odum L, Petersen HD, Andersen IB, Hansen BF, Rehfeld JF (1994) Gastrin and somatostatin in Helicobacter pylori infected antral mucosa. Gut 35: 615–618PubMedCrossRefGoogle Scholar
  6. Berger AC, Gibril F, Venzon DJ, Doppman JL, Norton JA, Bartlett DL, Libutti SK, Jensen RT, Alexander HR (2001) Prognostic value of initial fasting serum gastrin level in patients with Zollinger-Ellison syndrome. J Clin Oncol 19: 3051–3057PubMedGoogle Scholar
  7. Roy P, Venzon DJ, Feigenbaum KM, Koviack PD, Bashir S, Ojeaburu JV, Gibril F, Jensen RT (2001) Gastric secretion in Zollinger-Ellison syndrome: correlation with clinical expression, tumor extent and role in diagnosis – a prospective NIH study of 235 patients and review of the literature in 984 cases. Medicine (Baltimore) 80: 189–222CrossRefGoogle Scholar
  8. Frucht H, Howard JM, Slaff JF, Wank SA, McCarthy DM, Maton P, Vinayek R, Gardner JD, Jensen RT (1989) Secretin and calcium provocative tests in patients with Zollinger-Ellison syndrome: a prospective study. Ann Intern Med 111: 713–722PubMedGoogle Scholar
  9. Ganguli PL, Polak JM, Pearse AGE, Elder JB, Hegarty M (1974) Antra-gastrin cell hyperplasia in peptic ulcer disease. Lancet i: 583–586CrossRefGoogle Scholar
  10. Lamers CBH, Ruland CM, Joosten HJM, Verkooyen HCM, van Tongeren JHM, Rehfeld JF (1978) Hypergastrinemia of antral origin duodenal ulcer. Dig Dis 23: 998–1002CrossRefGoogle Scholar
  11. Graham DY, Opekun A, Lew GM, Klein PD, Walsh JH (1991) Helicobacter pylori-associated exaggerated gastrin release in duodenal ulcer patients. The effect of bombesin infusion and urea ingestion. Gastroenterology 100: 1571–1575PubMedGoogle Scholar
  12. Annibale B, Rindi G, D'Ambra G, Marignani M, Solcia E, Bordi C, Delle Fave G (1996) Antral gastrin cell hyperfunction and Helicobacter pylori infection. Aliment Pharmacol Ther 10: 607–615PubMedCrossRefGoogle Scholar
  13. Arnold R, Creutzfeldt C, Creutzfeldt W, Peiper HJ (1976) Befund beim Antrumrest nach Billroth-II-Operation ("excluded antrum") – ein Beitrag zur Differentialdiagnose des Rezidivulkus mit Hypergastrinämie. Verh Dtsch Ges Inn Med 82: 1002–1005PubMedGoogle Scholar
  14. Scobie BA, McGill DB, Priestly JT, Rovelstad RA (1964) Excluded antrum simulating the Zollinger-Ellison syndrome. Gastroenterology 47: 184–190PubMedGoogle Scholar
  15. Koop H, Klein M, Arnold R (1990) Serum gastrin levels during long-term omeprazole treatment. Aliment Pharmacol Ther 4: 131–138PubMedCrossRefGoogle Scholar
  16. Klingenberg-Knol EC, Festen HPM, Jansen JBMJ, Lamers CBHW, Nelis F, Snel P, Lückers A, Deckers CPM, Havu N, Meuwissen SGM (1994) Long-term treatment with omeprazole for refractory reflux oesophagitis. Ann Int Med 121: 161–167Google Scholar
  17. Eissele R, Brunner G, Simon B, Solcia E, Arnold R (1997) Gastric mucosa during treatment with lansoprazole: helicobacter pylori is a risk factor for argyrophil cell hyperplasia. Gastroenterology 112: 707–717PubMedCrossRefGoogle Scholar
  18. Bardhan KD, Cherian P, Bishop AE, Polak JM, Romanska H, Perry MJ, Rowland A, Thompson M, Morris P, Schneider A, Fischer R, Ng W, Luhmann R, AcCaldin B (2001) Pantoprazole therapy in the long-term management of severe acid peptic disease: clinical efficacy, safety, serum gastrin, gastric histology, and endocrine cell studies. Am J Gastroenterol 96: 1767–1776PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2007

Authors and Affiliations

  1. 1.Klinik für Innere Medizin, Schwerpunkt Gastroenterologie und Endokrinologie, Klinikum Giessen-Marburg, Standort MarburgPhilipps UniversitätMarburgGermany

Personalised recommendations